---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-24-248755"
form_type: "8-K"
ticker: "COYA"
cik: "0001835022"
company_name: "Coya Therapeutics, Inc."
filed_at: "2024-10-31T23:59:59+00:00"
generated_at: "2026-05-30T07:38:30.699025+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Coya Therapeutics appoints Arun Swaminathan as CEO, Howard Berman becomes Executive Chairman effective Nov 1, 2024

## Summary
- Swaminathan employment agreement provides $525,000 base salary, eligible for annual bonus up to 50% of base.
- Berman employment agreement provides $420,000 base salary, eligible for annual bonus up to 50% of base.
- Swaminathan becomes CEO on Nov 1, 2024; Berman resigns as CEO on Oct 31, 2024, remains on Board as Executive Chairman.
- Severance: if terminated without cause, 12 months base salary continuation plus prorated bonus for each.
- Non-compete for Swaminathan: 6 months post-termination, restricted to IL-2, CTLA-4 Ig, exosome product companies.

## SEC filing metadata
- accession: 0001193125-24-248755
- form_type: 8-K
- ticker: COYA
- cik: 0001835022
- company_name: Coya Therapeutics, Inc.
- filed_at: 2024-10-31T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1835022/000119312524248755/0001193125-24-248755-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1835022/000119312524248755/d840498d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-24-248755
- JSON: https://secwatch.observer/filing/0001193125-24-248755.json
- Plain text: https://secwatch.observer/filing/0001193125-24-248755.txt

## Key facts
- Executive change
  Howard Berman was appointed as Executive Chairman at Coya Therapeutics, Inc..
  - Action: resigned as Chief Executive Officer and appointed as Executive Chairman
  - Role: Executive Chairman
  source text: The Berman Employment Agreement provides for Dr. Berman to serve as Executive Chairman and provides for an annual base salary of $420,000.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1835022/000119312524248755/0001193125-24-248755-index.htm
- Executive change
  Arun Swaminathan was appointed as Chief Executive Officer at Coya Therapeutics, Inc..
  - Action: appointed
  - Role: Chief Executive Officer
  source text: Dr. Swaminathan was appointed as the Company’s Chief Executive Officer, effective November 1, 2024.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1835022/000119312524248755/0001193125-24-248755-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.